Cargando…

Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

BACKGROUND: While a low CD4/CD8 ratio during HIV treatment correlates with immunosenescence, its value in identifying patients at an increased risk for clinical events remains unclear. METHODS: We analyzed data from the CoRIS cohort to determine whether CD4 count, CD8 count, and CD4/CD8 ratio at yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Sanz, Javier, Díaz-Álvarez, Jorge, Rosas, Marta, Ron, Raquel, Iribarren, José Antonio, Bernal, Enrique, Gutiérrez, Félix, Ruiz Sancho, Andrés, Cabello, Noemi, Olalla, Julián, Moreno, Santiago, Serrano-Villar, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474064/
https://www.ncbi.nlm.nih.gov/pubmed/37639938
http://dx.doi.org/10.1016/j.ebiom.2023.104773
_version_ 1785100409714507776
author Martínez-Sanz, Javier
Díaz-Álvarez, Jorge
Rosas, Marta
Ron, Raquel
Iribarren, José Antonio
Bernal, Enrique
Gutiérrez, Félix
Ruiz Sancho, Andrés
Cabello, Noemi
Olalla, Julián
Moreno, Santiago
Serrano-Villar, Sergio
author_facet Martínez-Sanz, Javier
Díaz-Álvarez, Jorge
Rosas, Marta
Ron, Raquel
Iribarren, José Antonio
Bernal, Enrique
Gutiérrez, Félix
Ruiz Sancho, Andrés
Cabello, Noemi
Olalla, Julián
Moreno, Santiago
Serrano-Villar, Sergio
author_sort Martínez-Sanz, Javier
collection PubMed
description BACKGROUND: While a low CD4/CD8 ratio during HIV treatment correlates with immunosenescence, its value in identifying patients at an increased risk for clinical events remains unclear. METHODS: We analyzed data from the CoRIS cohort to determine whether CD4 count, CD8 count, and CD4/CD8 ratio at year two of antiretroviral therapy (ART) could predict the risk of serious non-AIDS events (SNAEs) during the next five years. These included major adverse cardiovascular events, non-AIDS-defining malignancies, and non-accidental deaths. We used pooled logistic regression with inverse probability weighting to estimate the survival curves and cumulative risk of clinical events. FINDINGS: The study included 4625 participants, 83% male, of whom 200 (4.3%) experienced an SNAE during the follow-up period. A CD4/CD8 ratio <0.3 predicted an increased risk of SNAEs during the next five years (OR 1.63, 95% CI 1.03–2.58). The effect was stronger at a CD4/CD8 ratio cut-off of <0.2 (OR 3.09, 95% CI 1.57–6.07). Additionally, low CD4 count at cut-offs of <500 cells/μL predicted an increased risk of clinical events. Among participants with a CD4 count ≥500 cells/μL, a CD8 count ≥1500 cells/μL or a CD4/CD8 ratio <0.4 predicted increased SNAE risk. INTERPRETATION: Our results support the use of the CD4/CD8 ratio and CD8 count as predictors of clinical progression. Patients with CD4/CD8 ratio <0.3 or CD8 count ≥1500/μL, regardless of their CD4 count, may benefit from closer monitoring and targeted preventive interventions. FUNDING: This work was supported by 10.13039/100006301CIBER (CB 2021), 10.13039/501100004587Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU; by the Spanish AIDS Research Network (RIS) RD16/0025/0001 project as part of the Plan Nacional R + D + I, and cofinanced by 10.13039/501100004587Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación y el 10.13039/501100008530Fondo Europeo de Desarrollo Regional (FEDER), ISCIII projects PI18/00154, PI21/00141, and ERDF, “A way to make Europe”, ICI20/00058.
format Online
Article
Text
id pubmed-10474064
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104740642023-09-03 Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events Martínez-Sanz, Javier Díaz-Álvarez, Jorge Rosas, Marta Ron, Raquel Iribarren, José Antonio Bernal, Enrique Gutiérrez, Félix Ruiz Sancho, Andrés Cabello, Noemi Olalla, Julián Moreno, Santiago Serrano-Villar, Sergio eBioMedicine Articles BACKGROUND: While a low CD4/CD8 ratio during HIV treatment correlates with immunosenescence, its value in identifying patients at an increased risk for clinical events remains unclear. METHODS: We analyzed data from the CoRIS cohort to determine whether CD4 count, CD8 count, and CD4/CD8 ratio at year two of antiretroviral therapy (ART) could predict the risk of serious non-AIDS events (SNAEs) during the next five years. These included major adverse cardiovascular events, non-AIDS-defining malignancies, and non-accidental deaths. We used pooled logistic regression with inverse probability weighting to estimate the survival curves and cumulative risk of clinical events. FINDINGS: The study included 4625 participants, 83% male, of whom 200 (4.3%) experienced an SNAE during the follow-up period. A CD4/CD8 ratio <0.3 predicted an increased risk of SNAEs during the next five years (OR 1.63, 95% CI 1.03–2.58). The effect was stronger at a CD4/CD8 ratio cut-off of <0.2 (OR 3.09, 95% CI 1.57–6.07). Additionally, low CD4 count at cut-offs of <500 cells/μL predicted an increased risk of clinical events. Among participants with a CD4 count ≥500 cells/μL, a CD8 count ≥1500 cells/μL or a CD4/CD8 ratio <0.4 predicted increased SNAE risk. INTERPRETATION: Our results support the use of the CD4/CD8 ratio and CD8 count as predictors of clinical progression. Patients with CD4/CD8 ratio <0.3 or CD8 count ≥1500/μL, regardless of their CD4 count, may benefit from closer monitoring and targeted preventive interventions. FUNDING: This work was supported by 10.13039/100006301CIBER (CB 2021), 10.13039/501100004587Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU; by the Spanish AIDS Research Network (RIS) RD16/0025/0001 project as part of the Plan Nacional R + D + I, and cofinanced by 10.13039/501100004587Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación y el 10.13039/501100008530Fondo Europeo de Desarrollo Regional (FEDER), ISCIII projects PI18/00154, PI21/00141, and ERDF, “A way to make Europe”, ICI20/00058. Elsevier 2023-08-26 /pmc/articles/PMC10474064/ /pubmed/37639938 http://dx.doi.org/10.1016/j.ebiom.2023.104773 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Martínez-Sanz, Javier
Díaz-Álvarez, Jorge
Rosas, Marta
Ron, Raquel
Iribarren, José Antonio
Bernal, Enrique
Gutiérrez, Félix
Ruiz Sancho, Andrés
Cabello, Noemi
Olalla, Julián
Moreno, Santiago
Serrano-Villar, Sergio
Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
title Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
title_full Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
title_fullStr Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
title_full_unstemmed Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
title_short Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
title_sort expanding hiv clinical monitoring: the role of cd4, cd8, and cd4/cd8 ratio in predicting non-aids events
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474064/
https://www.ncbi.nlm.nih.gov/pubmed/37639938
http://dx.doi.org/10.1016/j.ebiom.2023.104773
work_keys_str_mv AT martinezsanzjavier expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT diazalvarezjorge expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT rosasmarta expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT ronraquel expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT iribarrenjoseantonio expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT bernalenrique expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT gutierrezfelix expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT ruizsanchoandres expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT cabellonoemi expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT olallajulian expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT morenosantiago expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT serranovillarsergio expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents
AT expandinghivclinicalmonitoringtheroleofcd4cd8andcd4cd8ratioinpredictingnonaidsevents